Abstract Library

#2930 Treatment of the Pinealoma: Experience from a Rare Case

Introduction: Pinealoma is an extremely rare type of neuroendocrine tumor without evidence-based systemic therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: pinealoma, octreotide, interferon.,

#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Matheos de Lima B

Authors: Arruda Matheos de Lima B, Gonçalves R, Romano Gaspar P, Linhares Riello de Mello E, Oliveira Albagli R,

Keywords: peptide receptor radionuclide therapy, lutetium, collateral effects, hepatotoxicity, neuroendocrine tumor, hepatic steatosis,

#2039 Short-Term Change in Symptoms and Adverse Events Evaluation after PRRT – First Experience after 56 Patients

Introduction: From March 2016, patients with M+ NET are treated with PRRT at the Netherlands Cancer Institute.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Huizing D, Versleijen M, Geluk - Jonker M, Hendrikx J, De Wit - Van Der Veen L,

Keywords: PRRT, adverse events, clinical symptoms,

#1738 Sinonasal Neuroendocrine Small Blue Cell Tumour (SNBCT) Presenting with Bone Marrow Failure – A Very Rare Diagnostic and Therapeutic Challenge

Introduction: A 75 year old female presented with rapid onset right neck swelling and nasal bleeding. CT showed an infiltrative soft tissue mass involving the entire right nasal cavity and a lymph node mass in the right neck.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Dawes A, Duke S, Tahir Q, Leitch J, McStay M,

Keywords: Sinonasal, neuroendocrine, small, blue, cell, tumors, esthesioneuroblastoma, diagnosis, treatment, bone, marrow, metastases,

#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)

Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Del Prete M, Buteau F, Beauregard J,

Keywords: personalized, PRRT, neuroendocrine tumors ,